19,254 Shares in Royalty Pharma PLC $RPRX Acquired by Lido Advisors LLC

Lido Advisors LLC purchased a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the first quarter, Holdings Channel.com reports. The fund purchased 19,254 shares of the biopharmaceutical company’s stock, valued at approximately $924,000.

Other institutional investors have also recently bought and sold shares of the company. Morgan Stanley grew its holdings in shares of Royalty Pharma by 25.2% during the fourth quarter. Morgan Stanley now owns 55,274,069 shares of the biopharmaceutical company’s stock worth $2,135,790,000 after purchasing an additional 11,110,115 shares during the last quarter. Capital International Investors raised its holdings in shares of Royalty Pharma by 14.3% in the fourth quarter. Capital International Investors now owns 31,104,309 shares of the biopharmaceutical company’s stock valued at $1,201,870,000 after buying an additional 3,891,615 shares during the last quarter. Norges Bank acquired a new position in Royalty Pharma during the 4th quarter worth about $131,923,000. Qube Research & Technologies Ltd grew its holdings in Royalty Pharma by 737.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 2,481,771 shares of the biopharmaceutical company’s stock worth $87,557,000 after acquiring an additional 2,185,366 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Royalty Pharma by 379.2% during the 3rd quarter. Millennium Management LLC now owns 2,235,133 shares of the biopharmaceutical company’s stock worth $78,855,000 after acquiring an additional 1,768,702 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Insider Buying and Selling at Royalty Pharma

In other news, Director Gregory Norden sold 3,045 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the transaction, the director owned 191,803 shares of the company’s stock, valued at $10,165,559. This represents a 1.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 150,000 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $54.40, for a total value of $8,160,000.00. Following the completion of the transaction, the executive vice president owned 559,399 shares in the company, valued at $30,431,305.60. This represents a 21.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 393,009 shares of company stock valued at $21,601,827 in the last three months. Insiders own 18.84% of the company’s stock.

Royalty Pharma Stock Performance

Shares of NASDAQ:RPRX opened at $59.97 on Wednesday. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a 1-year low of $34.08 and a 1-year high of $60.08. The stock has a market capitalization of $34.53 billion, a P/E ratio of 40.80, a P/E/G ratio of 10.40 and a beta of 0.43. The business has a 50-day moving average price of $55.88 and a two-hundred day moving average price of $49.54.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The company had revenue of $630.58 million for the quarter, compared to analyst estimates of $881.69 million. Equities analysts predict that Royalty Pharma PLC will post 5.18 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. Royalty Pharma’s dividend payout ratio (DPR) is presently 63.95%.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. UBS Group increased their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. TD Cowen raised their price target on shares of Royalty Pharma from $50.00 to $65.00 and gave the company a “buy” rating in a report on Monday, July 13th. Morgan Stanley boosted their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. Finally, Weiss Ratings lowered Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 15th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and a consensus price target of $56.57.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.